RxDoctor Payments Data

Manuela Berry, NP

Family · San Antonio, TXNPI 1063070308

Payments from drug & device makers

$4,044in general payments, 2019–2025

Across 271 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$528
  • AstraZeneca$277
  • Merck$203
  • Bayer$167
  • GSK$163
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,044 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$24,532
Medicare patients
97
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$72,046
OzempicSemaglutide44$61,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$58,860
JardianceEmpagliflozin23$36,864
LinzessLinaclotide24$33,511
TrulicityDulaglutide17$30,761
VraylarCariprazine Hcl16$25,243
RybelsusSemaglutide14$19,580
FarxigaDapagliflozin Propanediol14$19,475
EliquisApixaban15$18,142
MyrbetriqMirabegron13$15,252
JanuviaSitagliptin Phosphate11$13,566
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,468
KerendiaFinerenone11$9,503
BelsomraSuvorexant16$7,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$114$102,80771 claims
Novo NordiskOzempic, Rybelsus$528$81,41758 claims
GSKTrelegy Ellipta$163$58,86040 claims
AbbVieLinzess, Vraylar$1,532$58,75440 claims
Boehringer IngelheimJardiance$156$36,86423 claims
MerckJanuvia, Belsomra$203$21,03027 claims
AstraZenecaFarxiga$277$19,47514 claims
PfizerEliquis$30$18,14215 claims
Astellas Pharma US IncMyrbetriq$10$15,25213 claims
BayerKerendia$167$9,50311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →